Edition:
United States

Genomic Health Inc (GHDX.OQ)

GHDX.OQ on NASDAQ Stock Exchange Global Select Market

31.76USD
4:00pm EDT
Change (% chg)

$0.41 (+1.31%)
Prev Close
$31.35
Open
$31.43
Day's High
$32.07
Day's Low
$31.39
Volume
49,824
Avg. Vol
81,870
52-wk High
$37.50
52-wk Low
$26.54

Chart for

About

Genomic Health, Inc. is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company's Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression... (more)

Overall

Beta: 0.62
Market Cap(Mil.): $1,127.91
Shares Outstanding(Mil.): 35.32
Dividend: --
Yield (%): --

Financials

  GHDX.OQ Industry Sector
P/E (TTM): -- 178.44 32.31
EPS (TTM): -0.11 -- --
ROI: -2.19 -0.73 12.97
ROE: -2.24 -2.77 14.84

BRIEF-Tailorx Results Aid In Assessing The Effect Of Chemotherapy In Women With Early-Stage Breast Cancer And Oncotype Dx Breast Recurrence Score Results Of 11 To 25

* LANDMARK TAILORX RESULTS AID IN ASSESSING THE EFFECT OF CHEMOTHERAPY IN WOMEN WITH EARLY-STAGE BREAST CANCER AND ONCOTYPE DX BREAST RECURRENCE SCORE® RESULTS OF 11 TO 25

Mar 15 2018

BRIEF-Genomic Health Reports Q4 Earnings Per Share $0.05

* GENOMIC HEALTH ANNOUNCES 2017 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS, PROVIDES 2018 FINANCIAL OUTLOOK

Mar 08 2018

BRIEF-Genomic Health Reports Q4 Earnings Per Share $0.05

* GENOMIC HEALTH ANNOUNCES 2017 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS, PROVIDES 2018 FINANCIAL OUTLOOK

Mar 08 2018

BRIEF-Genomic Health Expands Offering To Prostate Cancer Patients With Launch Of Oncotype DX AR-V7 Nucleus Detect Test To Predict Treatment Response In Metastatic Disease

* GENOMIC HEALTH EXPANDS OFFERING TO PROSTATE CANCER PATIENTS WITH LAUNCH OF ONCOTYPE DX® AR-V7 NUCLEUS DETECT™ TEST TO PREDICT TREATMENT RESPONSE IN METASTATIC DISEASE Source text for Eikon: Further company coverage:

Feb 26 2018

BRIEF-Genomic Health - Oncotype DX Genomic Prostate Score™ Test Increases Use Of Active Surveillance

* ONCOTYPE DX® GENOMIC PROSTATE SCORE™ TEST INCREASES USE OF ACTIVE SURVEILLANCE BY 30 PERCENT IN LOW-RISK PATIENTS, RESULTING IN GREATER ADHERENCE TO GUIDELINE-BASED CARE Source text for Eikon: Further company coverage:

Feb 05 2018

BRIEF-Genomic Health Announces Research Collaboration with Janssen Pharma

* GENOMIC HEALTH ANNOUNCES RESEARCH COLLABORATION WITH JANSSEN PHARMACEUTICALS TO EVALUATE THE ONCOTYPE DX® GENOMIC PROSTATE SCORE™ TEST FOR POTENTIAL DRUG DEVELOPMENT

Dec 06 2017

BRIEF-Genomic Health And Cleveland Diagnostics Announce Strategic Collaboration To Develop And Commercialize New Prostate Cancer Tests

* GENOMIC HEALTH AND CLEVELAND DIAGNOSTICS ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP AND COMMERCIALIZE NEW PROSTATE CANCER TESTS

Nov 28 2017

BRIEF-Genomic Health Q3 loss per share $0.06

* Genomic Health announces third quarter 2017 financial results and reports recent business progress

Nov 08 2017

Earnings vs. Estimates